Carry Life@ UF System Clinical Study

A Clinical Study With the Carry Life® UF System in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

The Carry Life UF system performs peritoneal ultrafiltration by adding glucose to the low glucose strength (1.36%) peritoneal dialysis fluid which has been instilled into the peritoneal cavity prior to the connection of the device. By maintaining a stable glucose concentration in the intraperitoneal fluid during the 5-hour treatment, the ultrafiltration can be increased compared to a standard CAPD dwell.

A study of the peritoneal ultrafiltration achieved with Carry Life® UF system compared to standard peritoneal dialysis (PD) therapy, in CAPD patients. The study consists of the following five (5) phases: Inclusion phase. In-clinic treatment phase for dose determination and safety evaluation. Randomization phase. Transition to home treatment phase. Home treatment phase for efficacy and safety evaluation. The in-clinic phase consists of one 2.27% Peritoneal equilibrium test (PET) and two Carry Life® UF treatments; one with a 11 g/h glucose dose and one with a 15 g/h glucose dose. The Carry Life® UF treatments will be used for a safety evaluation and based on the UF volumes achieved with the Carry Life® UF treatments, the Carry Life® UF glucose dose for the home treatment phase will be determined. A 24-h urine sample will be collected before the first visit for determination of residual renal function. After completion of the in-clinic treatment phase, subjects will be randomized to start the home treatment phase either with the control treatment arm or with the Carry Life® UF treatment arm. Subjects in the control arm will continue their standard CAPD treatment as prescribed. In the Carry Life® UF arm, for three days of the week one 2.27% glucose CAPD dwell per day will be replaced by a Carry Life® UF treatment. For the remaining four days of the week, one 2.27% glucose CAPD dwell will be replaced with a 1.36% glucose CAPD dwell. Immediately before the subject starts using the Carry Life® UF device at home, there will be a transition to the home treatment phase during which the subjects will undergo training on the device and an assessment of their device competency will be performed. During the home treatment phase of the study, the subject will record body weight, blood pressure and heart rate daily in a patient diary. The PD fill and drain volumes for each dwell during the study will be recorded, as well as any clinical symptoms or device malfunctions. At the start of the second and third week of each study arm of the home treatment phase a nurse will contact the subject to check on clinical status, AEs, and Carry Life® UF device malfunctions. Based on the clinical assessments throughout the study, the responsible physician will adjust the subject's PD prescription in order to maintain an adequate fluid balance according to clinical judgement and standard clinical practice. In the control arm, the glucose concentration of the PD dwells may be adjusted as required. Efficacy evaluation days: The efficacy evaluation days will be performed during week 2 and week 4 of each study arm during the home treatment phase. During the efficacy evaluation days the dialysate drained from the comparator 2.27% glucose dwell (control) and from the Carry Life® UF treatment will be collected by a research assistant for endpoint evaluation. The 2.27% glucose control dwell will be 5 hours i.e., the same duration as the Carry Life® UF treatment. The day after the completion of each arm (control and Carry Life® UF), the subject will visit the clinic for data collection. A 24-hour urine sample will be collected before each end-of-arm visit for determination of residual renal function.

Three days per week, the subject will replace a 2.27% glucose dwell with the Carry Life® UF treatment. The remaining four days of the week, one 2.27% glucose dwell will be replaced by a 1.36% glucose dwell.

The UF volume is the difference between the drained fluid volume and the administered fluid volume. The average of two treatments per arm during the home phase of the study.

Sodium removed with the drained fluid volume minus the sodium administered with the PD fluid. The average of two treatments per arm during the home phase of the study.

ml UF/gram glucose absorbed.Glucose absorbed is the glucose added with the solutions minus the glucose removed by the peritoneal drains. The average of two treatments per arm during the home phase of the study

The peak glucose concentration recorded during the two Carry Life UF treatments in the clinic phase of the study.

The amount of the urea and creatinine removed by the peritoneal drains. The average of two treatments for each arm during the home phase of the study.

Based on the PD diary. The sum of the UF volumes from all dwells during each study week during the home phase of the study

Inclusion Criteria: Age ≥ 18 years. Subjects with ESKD treated with PD for at least three (3) months. A PD prescription of 2-4 CAPD dwells/day unchanged for a minimum of two (2) weeks, with at least one 1.5-2L, 2.27% glucose day dwell daily. Subjects must be able to tolerate a 2 L PD fill volume for the PET. Subjects using the Baxter PD system with a MiniCap transfer set. In the opinion of the Investigator, the subject has the capacity to learn how to use the Carry Life® UF system or has a caregiver who can do so. Obtained written consent to participate in the study. Exclusion Criteria: A PD prescription including a regular 3.86% glucose day dwell. An episode of peritonitis within the last three (3) months. Serum potassium > 6 mmol/l within the last three (3) months. Serum urea > 35 mmol/l within the last three (3) months. Clinical signs of dehydration. Systolic blood pressure < 100 mmHg within the last month. Known diagnosis of clinically significant aortic stenosis. Clinical condition of unstable diabetes. Subjects with a life expectancy of < six (6) months. Evidence of any other diseases or medical conditions that may interfere with the planned treatment or affect participant compliance. Participation in clinical trials, interfering with the present study, within the previous month. Anticipated living donor kidney transplantation within six (6) months of screening. Pregnant, breastfeeding, or women of childbearing potential who are not using an effective method of contraception (hormonal contraceptives or barrier contraceptive methods).